World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://wjon.elmerpub.com

Original Article

Volume 000, Number 000, April 2025, pages 000-000

Co-expression of HER2/EGFRvIII/CD44 and Claudin 18.2/CD109 as Novel Prognostic Indicators in Stomach Adenocarcinoma

Figure 1. The immunohistochemical staining of HER family members, EGFRvIII, CD44, CD109, and CLDN18.2 in whole tumor specimens from patients with stomach adenocarcinoma (× 200 magnification). (a) EGFR 3+ membranous/cytoplasmic, (b) HER2 3+ membranous, (c) HER3 2+/3+ membranous, (d) HER4 1+ nuclear/cytoplasmic, (e) EGFRvIII 2+ cytoplasmic, (f) CD44 3+ membranous, (g) CD109 1+ membranous/cytoplasmic, (h) CLDN18.2 2+/3+ membranous, and (i) CLDN18.2 3+ in normal tissue and 2+ in tumor (arrow). CD44: cluster of differentiation 44; CD109: cluster of differentiation 109; CLDN18.2: claudin 18.2; EGFR: epidermal growth factor receptor; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor.

Figure 2. The prognostic significance and the association between the sub-categories of receptor expression and the OS of stomach cancer patients expressing EGFRvIII intensity 1+ (a), CD109 membranous expression (b), CLDN18.2 intensity 3+ (c), HER2/EGFRvIII at cut-off value of ≥ 5% (d), and HER2/EGFRvIII at cut-off value of ≥ 10% (e). A log-rank test value of P ≤ 0.05 was considered statistically significant. CD109: cluster of differentiation 109; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; OS: overall survival.

Figure 3. The prognostic significance and the association between the sub-categories of receptor expression and the OS of stomach cancer patients expressing HER2/EGFRvIII/CD44 at cut-off value of ≥ 5% (a), EGFRvIII/CD44 at cut-off value of ≥ 5% (b), EGFRvIII/CD44/CD109 at cut-off value of ≥ 5% (c), and CD109/CLDN18.2 at a cut-off value of ≥ 20% (d) in patients with stomach cancer. A log-rank test value of P ≤ 0.05 was considered statistically significant. CD44: cluster of differentiation 44; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; OS: overall survival.

**Table 1.** Patient Clinicopathological Characteristics and Association With Overall Survival Using Kaplan-Meier Analysis and Log-Rank Test in 78 Stomach Tumor Specimens
Characteristics	Number of patients (%)	Overall survival in years (mean ± SE)	95% CI	P-value
*Statistically significant. CI: confidence interval; SE: standard error.
Age				0.369
< 60	12 (15.4)	7.0 ± 1.5	4.0 - 10.0
≥ 60
Gender	66 (84.6)	6.3 ± 0.7	5.0 - 7.5	0.277
Male
Lauren classification	55 (70.5)	6.9 ± 0.8	5.3 - 8.5	0.394
Intestinal type	39 (50.6)	6.1 ± 0.8	4.5 - 7.7
Diffuse type/mixed type
T-stage	38 (44.2)	7.2 ± 0.9	5.3 - 9.1	0.185
T1 + T2	39 (50.0)	7.2 ± 0.8	5.6 - 8.9
T3 + T4
Grade	39 (50.0)	5.2 ± 0.7	3.8 - 6.7	0.353
< G3	22 (28.2)	5.6 ± 1.1	3.4 - 7.7
G3
Lymph node invasion	56 (71.8)	6.7 ± 0.7	5.2 - 8.1	0.030*
Absent	32 (41.0)	8.4 ± 1.8	6.1 - 10.7
Present
Lymphatic invasion	46 (59.0)	5.3 ± 0.7	4.0 - 6.7	0.575
Absent	32 (41.0)	6.9 ± 0.9	5.1 - 8.6
Present
Vascular invasion	46 (59.0)	6.4 ± 0.9	4.4 - 8.3	0.057
Absent	57 (73.1)	7.1 ± 0.8	5.6 - 8.6
Present
Perineural invasion	21 (26.9)	4.4 ± 0.8	2.9 - 5.9	0.019*
Absent	50 (64.1)	7.3 ± 0.8	5.9 - 8.8
Present	28 (35.9)	3.9 ± 0.7	2.5 - 5.3

Table 1. Patient Clinicopathological Characteristics and Association With Overall Survival Using Kaplan-Meier Analysis and Log-Rank Test in 78 Stomach Tumor Specimens

Characteristics

Number of patients (%)

Overall survival in years (mean ± SE)

95% CI

P-value

*Statistically significant. CI: confidence interval; SE: standard error.

Age

0.369

< 60

12 (15.4)

7.0 ± 1.5

4.0 - 10.0

≥ 60

Gender

66 (84.6)

6.3 ± 0.7

5.0 - 7.5

0.277

Male

Lauren classification

55 (70.5)

6.9 ± 0.8

5.3 - 8.5

0.394

Intestinal type

39 (50.6)

6.1 ± 0.8

4.5 - 7.7

Diffuse type/mixed type

T-stage

38 (44.2)

7.2 ± 0.9

5.3 - 9.1

0.185

T1 + T2

39 (50.0)

7.2 ± 0.8

5.6 - 8.9

T3 + T4

Grade

39 (50.0)

5.2 ± 0.7

3.8 - 6.7

0.353

< G3

22 (28.2)

5.6 ± 1.1

3.4 - 7.7

Lymph node invasion

56 (71.8)

6.7 ± 0.7

5.2 - 8.1

0.030*

Absent

32 (41.0)

8.4 ± 1.8

6.1 - 10.7

Present

Lymphatic invasion

46 (59.0)

5.3 ± 0.7

4.0 - 6.7

0.575

Absent

32 (41.0)

6.9 ± 0.9

5.1 - 8.6

Present

Vascular invasion

46 (59.0)

6.4 ± 0.9

4.4 - 8.3

0.057

Absent

57 (73.1)

7.1 ± 0.8

5.6 - 8.6

Present

Perineural invasion

21 (26.9)

4.4 ± 0.8

2.9 - 5.9

0.019*

Absent

50 (64.1)

7.3 ± 0.8

5.9 - 8.8

Present

28 (35.9)

3.9 ± 0.7

2.5 - 5.3

**Table 2.** Immunohistochemical Expression/Co-Expression of HER Family Members, EGFRvIII, CD44, CD109, and CLDN18.2
Receptor expression
Percentage of positive tumor cells, %
≥ 5%	10 (12.8)	64 (82.1)	7 (9.0)	26 (33.3)	26 (33.3)	32 (41.0)	47 (60.3)	31 (39.7)
≥ 10%	6 (7.7)	60 (76.9)	4 (5.1)	19 (24.4)	17 (21.8)	31 (39.7)	44 (56.4)	24 (30.8)
≥ 20%	3 (3.8)	53 (67.9)	2 (2.6)	15 (19.2)	10 (12.8)	24 (34.6)	34 (43.6)	17 (21.8)
≥ 50%	1 (1.3)	28 (35.9)	0	4 (5.1)	7 (9.0)	13 (15.7)	20 (23.3)	13 (16.7)
Intensity
1+	8 (10.3)	34 (43.6)	4 (5.1)	25 (32.1)	20 (25.6)	14 (17.9)	47 (60.3)	19 (24.4)
2+	0	32 (41.0)	4 (5.1)	1 (1.3)	11 (14.1)	16 (20.5)	1 (1.3)	14 (17.9)
3+	2 (2.6)	6 (7.7)	2 (2.6)	0	0	14 (17.9)	0	6 (7.7)
Sub-cellular localization
Membranous	3 (3.8)	10 (12.8)	5 (6.4)	0	0	32 (41.0)	17 (19.8)	31 (39.7)
Cytoplasmic	10 (12.8)	61 (78.2)	3 (2.8)	17 (21.8)	25 (32.1)	0	47 (60.3)	0
Nuclear	0	0	0	22 (28.2)	2 (2.6)	0	0	0
CD: cluster of differentiation; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; wt: wild-type.
Wt-EGFR/HER2	7 (9.0)	4 (5.1)	1 (1.3)	0
Wt-EGFR/CD109	8 (10.3)	6 (7.7)	3 (3.8)	1 (1.3)
HER2/HER4	21 (26.9)	14 (17.9)	11 (14.1)	1 (1.3)
HER2/EGFRvIII	22 (28.2)	12 (15.4)	4 (5.1)	0
HER2/CD44	26 (33.3)	21 (26.9)	16 (20.5)	4 (5.1)
HER2/CD109	38 (48.7)	34 (43.6)	24 (30.8)	10 (12.8)
HER2/CLDN18.2	25 (32.1)	19 (24.4)	13 (16.7)	4 (5.1)
HER2/EGFRvIII/CD44	9 (11.5)	4 (5.1)	4 (5.1)	0
HER2/EGFRvIII/CD109	13 (16.7)	5 (6.4)	1 (1.3)	0
HER2/CD44/CD109	20 (25.6)	16 (20.5)	10 (12.8)	3 (3.8)
HER2/CD44/CLDN18.2	13 (16.7)	9 (11.5)	3 (3.8)	0
HER2/CD44/CD109/CLDN18.2	12 (15.4)	9 (11.5)	2 (2.6)	0
HER2/ CD109/CLDN18.2	20 (25.6)	16 (20.5)	9 (11.5)	2 (2.6)
HER4/EGFRvIII	7 (9.0)	1 (1.3)	0	0
HER4/CD44	15 (19.2)	8 (10.3)	7 (9.0)	0
HER4/CD109	19 (24.4)	16 (20.5)	8 (10.3)	1 (1.3)
HER4/CLDN18.2	13 (16.7)	8 (10.3)	4 (5.1)	0
HER4/CD44/CD109	11 (14.1)	7 (9.0)	5 (6.4)	0
HER4/CD44/CLDN18.2	8 (10.3)	3 (3.8)	0	0
HER4/CD109/CLDN18.2	13 (16.7)	8 (10.3)	3 (3.8)	0
HER4/CD44/CD109/CLDN18.2	8 (10.3)	3 (3.6)	0	0
EGFRvIII/CD44	10 (12.8)	4 (5.1)	4 (5.1)	1 (1.3)
EGFRvIII/CD109	14 (17.9)	6 (7.7)	2 (2.6)	0
EGFRvIII/CLDN18.2	10 (12.8)	2 (2.6)	0	0
EGFRvIII/CD44/CD109	8 (10.3)	3 (3.8)	1 (1.3)	0
EGFRvIII/CD109/CLDN18.2	7 (9.0)	2 (2.6)	0	0
CD44/CD109	24 (30.8)	20 (25.6)	13 (16.7)	5 (6.4)
CD44/CLDN18.2	15 (19.2)	11 (14.1)	3 (3.8)	2 (2.6)
CD44/CD109/CLDN18.2	14 (17.9)	10 (12.8)	2 (2.6)	1 (1.3)
CD109/CLDN18.2	25 (32.1)	21 (26.0)	12 (15.4)	(6.4)

Table 2. Immunohistochemical Expression/Co-Expression of HER Family Members, EGFRvIII, CD44, CD109, and CLDN18.2

Receptor expression

Scoring criteria

Wt-EGFR

HER2

HER3

HER4

EGFRvIII

CD44

CD109

CLDN18.2

Percentage of positive tumor cells, %

≥ 5%

10 (12.8)

64 (82.1)

7 (9.0)

26 (33.3)

32 (41.0)

47 (60.3)

31 (39.7)

≥ 10%

6 (7.7)

60 (76.9)

4 (5.1)

19 (24.4)

17 (21.8)

31 (39.7)

44 (56.4)

24 (30.8)

≥ 20%

3 (3.8)

53 (67.9)

2 (2.6)

15 (19.2)

10 (12.8)

24 (34.6)

34 (43.6)

17 (21.8)

≥ 50%

1 (1.3)

28 (35.9)

4 (5.1)

7 (9.0)

13 (15.7)

20 (23.3)

13 (16.7)

Intensity

8 (10.3)

34 (43.6)

4 (5.1)

25 (32.1)

20 (25.6)

14 (17.9)

47 (60.3)

19 (24.4)

32 (41.0)

4 (5.1)

1 (1.3)

11 (14.1)

16 (20.5)

1 (1.3)

14 (17.9)

2 (2.6)

6 (7.7)

2 (2.6)

14 (17.9)

6 (7.7)

Sub-cellular localization

Membranous

3 (3.8)

10 (12.8)

5 (6.4)

32 (41.0)

17 (19.8)

31 (39.7)

Cytoplasmic

10 (12.8)

61 (78.2)

3 (2.8)

17 (21.8)

25 (32.1)

47 (60.3)

Nuclear

22 (28.2)

2 (2.6)

Co-expression

Markers

≥ 5% cut-off

≥ 10% cut-off

≥ 20% cut-off

≥ 50% cut-off

CD: cluster of differentiation; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; wt: wild-type.

Wt-EGFR/HER2

7 (9.0)

4 (5.1)

1 (1.3)

Wt-EGFR/CD109

8 (10.3)

6 (7.7)

3 (3.8)

1 (1.3)

HER2/HER4

21 (26.9)

14 (17.9)

11 (14.1)

1 (1.3)

HER2/EGFRvIII

22 (28.2)

12 (15.4)

4 (5.1)

HER2/CD44

26 (33.3)

21 (26.9)

16 (20.5)

4 (5.1)

HER2/CD109

38 (48.7)

34 (43.6)

24 (30.8)

10 (12.8)

HER2/CLDN18.2

25 (32.1)

19 (24.4)

13 (16.7)

4 (5.1)

HER2/EGFRvIII/CD44

9 (11.5)

4 (5.1)

HER2/EGFRvIII/CD109

13 (16.7)

5 (6.4)

1 (1.3)

HER2/CD44/CD109

20 (25.6)

16 (20.5)

10 (12.8)

3 (3.8)

HER2/CD44/CLDN18.2

13 (16.7)

9 (11.5)

3 (3.8)

HER2/CD44/CD109/CLDN18.2

12 (15.4)

9 (11.5)

2 (2.6)

HER2/ CD109/CLDN18.2

20 (25.6)

16 (20.5)

9 (11.5)

2 (2.6)

HER4/EGFRvIII

7 (9.0)

1 (1.3)

HER4/CD44

15 (19.2)

8 (10.3)

7 (9.0)

HER4/CD109

19 (24.4)

16 (20.5)

8 (10.3)

1 (1.3)

HER4/CLDN18.2

13 (16.7)

8 (10.3)

4 (5.1)

HER4/CD44/CD109

11 (14.1)

7 (9.0)

5 (6.4)

HER4/CD44/CLDN18.2

8 (10.3)

3 (3.8)

HER4/CD109/CLDN18.2

13 (16.7)

8 (10.3)

3 (3.8)

HER4/CD44/CD109/CLDN18.2

8 (10.3)

3 (3.6)

EGFRvIII/CD44

10 (12.8)

4 (5.1)

1 (1.3)

EGFRvIII/CD109

14 (17.9)

6 (7.7)

2 (2.6)

EGFRvIII/CLDN18.2

10 (12.8)

2 (2.6)

EGFRvIII/CD44/CD109

8 (10.3)

3 (3.8)

1 (1.3)

EGFRvIII/CD109/CLDN18.2

7 (9.0)

2 (2.6)

CD44/CD109

24 (30.8)

20 (25.6)

13 (16.7)

5 (6.4)

CD44/CLDN18.2

15 (19.2)

11 (14.1)

3 (3.8)

2 (2.6)

CD44/CD109/CLDN18.2

14 (17.9)

10 (12.8)

2 (2.6)

1 (1.3)

CD109/CLDN18.2

25 (32.1)

21 (26.0)

12 (15.4)

(6.4)

**Table 3.** Association Between Clinicopathological Characteristics and Protein Expression Using Chi-Square Test (FET)
Receptor (sub-categories)	Clinicopathological parameters	Chi-square test (FET)
CD: cluster of differentiation; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; FET: Fisher’s exact t-test; HER2: human epidermal growth factor receptor 2; wt: wild-type.
	Age
	< 60	≥ 60
HER2/CLDN18.2 (≥ 5%)	0	25	0.010 (0.007)
HER2/CLDN18.2 (≥ 10%)	0	19	0.033 (0.032)
HER2/CD109/CLDN18.2 (≥ 5%)	0	20	0.027 (0.030)
	Lauren classification
	Intestinal type	Diffuse/mixed type
HER2/CD44/CLDN18.2 (≥ 5%)	3	10	0.026 (0.034)
	T-stage
	T1 + T2	T3 + T4
HER2 (intensity 1+)	12	22	0.022 (0.039)
EGFRvIII (≥ 5%)	6	20	0.0008 (0.002)
EGFRvIII (cytoplasmic)	6	19	0.002 (0.003)
EGFRvIII (intensity 1+)	5	15	0.010 (0.018)
HER2/HER4 (≥ 5%)	15	6	0.022 (0.040)
HER2/EGFRvIII (≥ 5%)	6	16	0.012 (0.022)
	Vascular invasion
	Absent	Present
Wt-EGFR (≥ 10%)	1	5	0.001 (0.005)
Wt-EGFR (membranous)	0	3	0.004 (0.017)
EGFRvIII (cytoplasmic)	14	11	0.020 (0.029)
EGFRvIII (intensity 1+)	11	9	0.035 (0.044)
Wt-EGFR/CD109 (≥ 5%)	3	5	0.017 (0.029)
Wt-EGFR/CD109 (≥ 10%)	1	5	0.001 (0.005)
	Lymphatic invasion
	Absent	Present
Wt-EGFR (≥ 5%)	0	10	0.005 (0.004)
Wt-EGFR (cytoplasmic)	0	10	0.005 (0.004)
Wt-EGFR (intensity 1+)	0	8	0.013 (0.018)
EGFRvIII (≥ 5%)	5	21	0.006 (0.007)
EGFRvIII (cytoplasmic)	5	20	0.010 (0.013)
EGFRvIII (intensity 1+)	3	17	0.006 (0.008)
Wt-EGFR/HER2 (≥ 5%)	0	7	0.021 (0.037)
Wt-EGFR/CD109 (≥ 5%)	0	8	0.013 (0.018)
HER2/EGFRvIII (≥ 5%)	4	18	0.010 (0.011)
HER4/EGFRvIII (≥ 5%)	0	7	0.021 (0.037)
	Perineural invasion
	Absent	Present
CLDN18.2 (≥ 20%)	7	10	0.026 (0.043)
	Grade
	< G3	G3
HER2 (membranous)	7	3	0.002 (0.004)
HER2 (intensity 1+)	5	29	0.020 (0.024)
CD109 (≥ 10%)	17	27	0.020 (0.024)
CD109 (membranous)	10	7	0.002 (0.004)
HER2/CD109 (≥ 5%)	16	22	0.008 (0.011)
HER2/CD109 (≥ 10%)	16	18	0.001 (0.002)

Table 3. Association Between Clinicopathological Characteristics and Protein Expression Using Chi-Square Test (FET)

Receptor (sub-categories)

Clinicopathological parameters

Chi-square test (FET)

Number of patients with receptor expression

CD: cluster of differentiation; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; FET: Fisher’s exact t-test; HER2: human epidermal growth factor receptor 2; wt: wild-type.

Age

< 60

≥ 60

HER2/CLDN18.2 (≥ 5%)

0.010 (0.007)

HER2/CLDN18.2 (≥ 10%)

0.033 (0.032)

HER2/CD109/CLDN18.2 (≥ 5%)

0.027 (0.030)

Lauren classification

Intestinal type

Diffuse/mixed type

HER2/CD44/CLDN18.2 (≥ 5%)

0.026 (0.034)

T-stage

T1 + T2

T3 + T4

HER2 (intensity 1+)

0.022 (0.039)

EGFRvIII (≥ 5%)

0.0008 (0.002)

EGFRvIII (cytoplasmic)

0.002 (0.003)

EGFRvIII (intensity 1+)

0.010 (0.018)

HER2/HER4 (≥ 5%)

0.022 (0.040)

HER2/EGFRvIII (≥ 5%)

0.012 (0.022)

Vascular invasion

Absent

Present

Wt-EGFR (≥ 10%)

0.001 (0.005)

Wt-EGFR (membranous)

0.004 (0.017)

EGFRvIII (cytoplasmic)

0.020 (0.029)

EGFRvIII (intensity 1+)

0.035 (0.044)

Wt-EGFR/CD109 (≥ 5%)

0.017 (0.029)

Wt-EGFR/CD109 (≥ 10%)

0.001 (0.005)

Lymphatic invasion

Absent

Present

Wt-EGFR (≥ 5%)

0.005 (0.004)

Wt-EGFR (cytoplasmic)

0.005 (0.004)

Wt-EGFR (intensity 1+)

0.013 (0.018)

EGFRvIII (≥ 5%)

0.006 (0.007)

EGFRvIII (cytoplasmic)

0.010 (0.013)

EGFRvIII (intensity 1+)

0.006 (0.008)

Wt-EGFR/HER2 (≥ 5%)

0.021 (0.037)

Wt-EGFR/CD109 (≥ 5%)

0.013 (0.018)

HER2/EGFRvIII (≥ 5%)

0.010 (0.011)

HER4/EGFRvIII (≥ 5%)

0.021 (0.037)

Perineural invasion

Absent

Present

CLDN18.2 (≥ 20%)

0.026 (0.043)

Grade

< G3

HER2 (membranous)

0.002 (0.004)

HER2 (intensity 1+)

0.020 (0.024)

CD109 (≥ 10%)

0.020 (0.024)

CD109 (membranous)

0.002 (0.004)

HER2/CD109 (≥ 5%)

0.008 (0.011)

HER2/CD109 (≥ 10%)

0.001 (0.002)

**Table 4.** Association Between Expression of HER Family Members and Overall Survival in Univariate and Multivariate Analysis
Expression	Univariate	Multivariate
CD: cluster of differentiation; CI: confidence interval; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; NS: non-significant.
EGFRvIII intensity 1+	NS			NS
CD109 membranous	2.04	1.02 - 4.07	0.042	2.27	1.06 - 3.87	0.022
CLDN18.2 intensity 3+	2.36	0.90 - 5.65	0.050	2.62	1.09 - 3.87	0.031
HER2/EGFRvIII ≥ 5%	1.89	1.02 - 3.49	0.041	1.96	1.06 - 3.65	0.031
HER2/EGFRvIII ≥ 10%	2.24	1.06 - 4.73	0.033	2.45	1.15 - 5.21	0.020
EGFRvIII/CD44 ≥ 5%	2.97	1.33 - 6.61	0.008	2.97	1.33 - 6.61	0.008
CD109/CLDN18.2 ≥ 20%	2.16	1.05 - 4.43	0.035	2.06	1.00 - 4.25	0.048
HER2/EGFRvIII/CD44 ≥ 5%	2.68	1.16 - 6.20	0.021	2.68	1.16 - 6.20	0.021
EGFRvIII/CD44/CD109 ≥ 5%	4.21	1.79 - 9.98	0.0009	4.21	1.79 - 9.98	0.0009

Table 4. Association Between Expression of HER Family Members and Overall Survival in Univariate and Multivariate Analysis

Expression

Univariate

Multivariate

Hazard ratio

95% CI

P-value

Hazard ratio

95% CI

P-value

CD: cluster of differentiation; CI: confidence interval; CLDN18.2: claudin 18.2; EGFRvIII: epidermal growth factor receptor variant III; HER2: human epidermal growth factor receptor 2; NS: non-significant.

EGFRvIII intensity 1+

CD109 membranous

2.04

1.02 - 4.07

0.042

2.27

1.06 - 3.87

0.022

CLDN18.2 intensity 3+

2.36

0.90 - 5.65

0.050

2.62

1.09 - 3.87

0.031

HER2/EGFRvIII ≥ 5%

1.89

1.02 - 3.49

0.041

1.96

1.06 - 3.65

0.031

HER2/EGFRvIII ≥ 10%

2.24

1.06 - 4.73

0.033

2.45

1.15 - 5.21

0.020

EGFRvIII/CD44 ≥ 5%

2.97

1.33 - 6.61

0.008

2.97

1.33 - 6.61

0.008

CD109/CLDN18.2 ≥ 20%

2.16

1.05 - 4.43

0.035

2.06

1.00 - 4.25

0.048

HER2/EGFRvIII/CD44 ≥ 5%

2.68

1.16 - 6.20

0.021

2.68

1.16 - 6.20

0.021

EGFRvIII/CD44/CD109 ≥ 5%

4.21

1.79 - 9.98

0.0009

4.21

1.79 - 9.98

0.0009